Zepzelca
What Zepzelca is used for
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
Approved use, as published by the European Medicines Agency.
What the labels mean
- Orphan medicine: for a rare disease (affecting no more than 5 in 10,000 people in the EU).
Key facts
- Brand
- Zepzelca
- Active substance
- lurbinectedin
- Disease area
- Small Cell Lung Carcinoma
- Medicine group
- Antineoplastic agents
- ATC code
- L01XX69
- Marketing authorisation holder
- Pharma Mar S.A.
- Authorised in the EU since
- 2026
Official information
In the USA
Same active substance: Zepzelca
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Zepzelca used for?
Zepzelca, in combination with atezolizumab, is indicated for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab, carboplatin and etoposide.
What is the active substance in Zepzelca?
Zepzelca contains lurbinectedin.
Who makes Zepzelca?
The EU marketing authorisation holder is Pharma Mar S.A..
Is Zepzelca an orphan medicine?
Yes. Zepzelca is designated an orphan medicine in the EU, for a rare disease (Small Cell Lung Carcinoma).
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU